Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2007
07/19/2007US20070166412 Aspirin formulation for cardiovascular health
07/19/2007US20070166411 Nutritional supplement containing long-chain polyunsaturated fatty acids
07/19/2007US20070166409 Therapeutic compositions containing trimethoprim and cranberry extract and methods for treating and preventing urinary tract infections
07/19/2007US20070166408 Composition and method to augment and sustain neurotransmitter production
07/19/2007US20070166402 Compositions, methods and kits for removing debris from an ocular area
07/19/2007US20070166401 Anticancer or antiviral composition
07/19/2007US20070166400 Pharmaceutical composition comprising i.a. vitamin c, magnesium green tea extract for retarding cardiovascular disease
07/19/2007US20070166390 Method for cancer therapy using herbal extracts
07/19/2007US20070166385 Method of inhibiting restenosis using bisphosphonates
07/19/2007US20070166384 Methods , composition and preparations for delivery of immune response modifiers
07/19/2007US20070166383 Anionic hydrogel matrices with ph dependent modified release as drug carriers
07/19/2007US20070166382 Bioresponsive polymer system for delivery of microbicides
07/19/2007US20070166380 Zolpidem tablets
07/19/2007US20070166379 Coated tablet containing venlafaxin or its salts with controlled release
07/19/2007US20070166378 Oral ribavirin pharmaceutical compositions
07/19/2007US20070166376 Solid pharmaceutical preparation
07/19/2007US20070166375 Modified release oral dosage form using co-polymer of polyvinyl acetate
07/19/2007US20070166374 Orally administering edible oil homogenized with an edible wax and stigmasterol, campesterol, beta -sitosterol, chalinosterol, clionasterol, brassicasterol, alpha -spinasterol, daucosterol, desmosterol, and/or poriferasterol; repairing and promoting regeneration of mucosa in gastrointestinal tract
07/19/2007US20070166372 Preparation of solid coprecipitates of amorphous valsartan
07/19/2007US20070166370 Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
07/19/2007US20070166369 Photodynamic cosmetic procedure and healing method
07/19/2007US20070166368 Protein-Stabilized Liposomal Formulations of Pharmaceutical Agents
07/19/2007US20070166367 Adept or gdept producing acetaldehyde
07/19/2007US20070166365 Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
07/19/2007US20070166364 Transdermal Therapeutic System
07/19/2007US20070166363 Use of cholinesterase inhibitors for treating vascular depression
07/19/2007US20070166361 Formulations for transdermal or transmucosal application
07/19/2007US20070166360 External preparation
07/19/2007US20070166354 Method of reducing the risk of retinopathy of prematurity in preterm infants
07/19/2007US20070166352 polyglycolic acid or polylactic acid or glycolic acid-lactic acid copolymer as biocompatible polymer having dispersed therein an active agent such as exendin-4; antidiabetic agent
07/19/2007US20070166348 Keratin bioceramic compositions
07/19/2007US20070166346 Method for coating an object with hydrophobin at low temperatures
07/19/2007US20070166344 Non-leaching surface-active film compositions for microbial adhesion prevention
07/19/2007US20070166337 Skincare compositions and methods
07/19/2007US20070166336 Stable and palatable oral liquid sumatriptan compositions
07/19/2007US20070166329 Containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus; Japanese encephalitis virus (JEV), West Nile virus (WNV) or related flaviviruses
07/19/2007US20070166321 Compositions and Methods for Reducing Cholesterol and Inflammation
07/19/2007US20070166318 Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
07/19/2007US20070166314 EpA2 monoclonal antibodies and methods of use thereof
07/19/2007US20070166312 Antibody against tumor specific antigen as target
07/19/2007US20070166306 Anti-CD19 antibody composition and method
07/19/2007US20070166299 Treatment for embolic stroke
07/19/2007US20070166296 Therapeutic Systems
07/19/2007US20070166295 Anti-Diarrhea Preparations for Small Domestic Animals
07/19/2007US20070166281 Chloroquine coupled antibodies and other proteins with methods for their synthesis
07/19/2007US20070166277 Polymeric reagents comprising a ketone or a related functional group
07/19/2007US20070166276 Useful in extending the in vivo circulating life of biologically active materials; bicine linker allows for the manipulation of the hydrolysis rate of the prodrug, thereby releasing the native entities at various rates in vivo as well as in vitro
07/19/2007US20070166259 Cosmetic composition comprising a tensioning agent and a particular block ethylenic polymer
07/19/2007US20070166249 Pharmaceutical and cosmetic formulations for treating fingernails
07/19/2007US20070166241 Salicylic acid acne spray formulations and methods for treating acne with same
07/19/2007US20070166240 0.08 mu g/mL up to 128 mu g/mL formoterol or a derivative in water that is stable during long term storage; intended for administration as a nebulized aerosol for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders
07/19/2007US20070166237 Method for the treatment of bone disorders
07/19/2007US20070166236 Formoterol or derivative in water for long term storage stability; nebulized aerosol
07/19/2007US20070166235 Bronchodilating beta-agonist compositions and methods
07/19/2007US20070166234 Analgesically effective amount of opioid analgesic is combined with polymer to form a matrix, contains a surfactant in sufficient amount to cause nasal irritation; dosage form is abuse deterrent
07/19/2007US20070163610 Formulation and Use and Manufacture Thereof
07/19/2007DE4131276B4 Peroral applizierbare Metoclopramidlösungen Orally administered Metoclopramidlösungen
07/19/2007DE102006002509A1 Verfahren zur Herstellung von Dimethylaminoarglabin-Hydrochlorid A process for preparing Dimethylaminoarglabin hydrochloride
07/19/2007DE102006001994A1 Zusammensetzung und Methode einer topischen Therapie abdominaler Reiz- und Schmerz-Symptomatiken Composition and method of topical therapy of abdominal irritation and pain pathologies
07/19/2007DE102006001574A1 Acylaminoimidazole Acylaminoimidazole
07/19/2007DE102005057912A1 In 3-Position heterocyclisch substituierte Pyrrolidin(thi)one In the 3-position hetero-substituted pyrrolidine (thi) ones
07/19/2007DE102005057178A1 Verwendung von Zinksalzen der Liponsäure zur Behandlung von Fettstoffwechselstörungen Use of zinc salts of lipoic acid in the treatment of dyslipidemia
07/19/2007DE102005055963A1 Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum Aerosol formulation for inhalation containing an anticholinergic
07/19/2007DE102005055960A1 Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum Aerosol formulation for inhalation containing an anticholinergic
07/19/2007DE102005055958A1 Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum Aerosol formulation for inhalation containing an anticholinergic
07/19/2007CA2849559A1 Methods of modulating cell surface receptors to prevent or reduce inflammation
07/19/2007CA2640897A1 Combination of triazine derivatives and insulin sensitisers
07/19/2007CA2637418A1 Serotonergic agents for treating sexual dysfunction
07/19/2007CA2637388A1 Pyrrolopyridazinone compound
07/19/2007CA2637069A1 Combination of mtor inhibitor and antipolate compound
07/19/2007CA2637045A1 Tri-substituted 2-benzhydryl-5-benzlamino-tetrahydro-pyran-4-ol and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-ol analogues, and novel 3,6-disubstituted pyran derivatives
07/19/2007CA2637006A1 Trpm2-specific inhibitors
07/19/2007CA2637000A1 Methods and compositions for treating prostate cancer, benign prostatic hypertrophy, polycystic ovary syndrome and other conditions
07/19/2007CA2636946A1 Fused triazole tachykinin receptor antagonists
07/19/2007CA2636941A1 Drug combinations
07/19/2007CA2636841A1 Combination of triazine derivatives and ppar.alpha. agonists
07/19/2007CA2636840A1 Combination of triazine derivatives and hmg- coa reductase inhibitors for the treatment of diabetes
07/19/2007CA2636838A1 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect
07/19/2007CA2636837A1 Combination of triazine derivatives and insulin secretion stimulators
07/19/2007CA2636663A1 Solid pharmaceutical composition comprising irbesartan
07/19/2007CA2636638A1 A method of treating an acute vascular disorder
07/19/2007CA2636625A1 Oxazolone derivative
07/19/2007CA2636618A1 Oral s-adenosylmethionine compositions
07/19/2007CA2636545A1 Urotensin ii receptor antagonists
07/19/2007CA2636527A1 Viral hepatitis treatment
07/19/2007CA2636336A1 Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions
07/19/2007CA2636333A1 Compositions and methods of treatment using modulators of motonueron diseases
07/19/2007CA2636275A1 Tetralone-based monoamine reuptake inhibitors
07/19/2007CA2636274A1 Salts of potassium atp channel openers and uses thereof
07/19/2007CA2636149A1 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
07/19/2007CA2636142A1 Treatment modalities for autoimmune diseases
07/19/2007CA2636119A1 Bioadhesive drug formulations for oral transmucosal delivery
07/19/2007CA2635982A1 6-phenyl-1h-imidazo[4, 5-c]pyridine-4-carbonitrile derivatives as cathepsin k and s inhibitors
07/19/2007CA2635950A1 Mutilin derivatives and their use as pharmaceutical
07/19/2007CA2635949A1 Controlled release formulation of divalproic acid and its derivatives
07/19/2007CA2635916A1 Triazoloanilinopyrimidine derivatives for use as antiviral agents
07/19/2007CA2635894A1 Methods and compositions for administration of iron
07/19/2007CA2635825A1 Use of cns penetrating anticancer compounds for the treatment of protozan diseases
07/19/2007CA2635787A1 Cycloalkanecarboxamide derivative and method for producing same
07/19/2007CA2635719A1 Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators